Biotech Co.* (Country; Symbol)
Pharma Co. (Country)
Aero Pharmaceuticals Inc.*
Akorn will provide contract manufacturing services for Aero
Details on the terms and products were not disclosed (5/6)
Avanir Pharmaceuticals Inc. (AMEX:AVN)
Gerolymatos Group of Companies (Greece)
Gerolymatos got exclusive rights to Avanir's docosanol 10% cream in Greece, Cyprus, Turkey and Romania
Avanir will receive a data-transfer fee, a potential milestone payment and royalties on any sales of the product, which is sold in the U.S. as Abreva for cold sores (6/14)
Carrington Laboratories Inc. (CARN)
Medline Industries Inc.
Extension of deal under which Medline will sell Carrington's wound and skin-care products
The deal, set to expire in November 2005, was extended through November 2008; Carrington gets a $1.25M royalty paymentand will continue manufacturing products (4/22)
Corixa Corp. (CRXA)
Australian Nuclear Science and Technology Organization (Australia)
ANSTO got exclusive rights to develop and sell Bexxar in much of the Australia-Asia region and coexclusive rights in Japan, South Korea and Taiwan
Under the 12-year deal, ANSTO will pay Corixa an up-front licensing fee and regulatory milestone payments, as well as payments based on sales volume and royalties on sales (5/19)
DSM will produce a commercial supply of HuMax-CD4
DSM will manufacture Genmab's antibody (Denmark; CSE:GEN) for T-cell lymphoma, both for clinical trials and subsequent commercialization (6/1)
Guilford Pharmaceuticals Inc. (GLFD)
Link Pharmaceuticals Ltd. (UK)
Link will distribute the Gliadel Wafer in Germany, Switzerland, France, Benelux and Austria
Link already sells the product for brain cancer in the UK; Guilford got $500,000 up front and could get up to $2M in milestone payments; Link is responsible for getting approvals in the covered countries (5/17)
Isotechnika Inc. (Canada; TSE: ISA)
Lonza Group Ltd. (Switzerland)
Lonza will manufacture Isotechnika's trans-ISA247 for upcoming clinical trials
The companies formalized a manufacturing deal; terms were not disclosed (6/8)
Matritech Inc. (AMEX:MZT)
Inverness Medical Innovations Inc.
Deal for the distribution of Matritech's NMP22 Test Kit for cancer detection
Inverness subsidiary Wampole Laboratories LLC got exclusive rights to sell to hospitals and laboratories in the U.S. (6/7)
MedImmune Inc. (MEDI)
Henry Schein Inc.
Henry Schein was named exclusive U.S. distributor of FluMist for the upcoming flu season
MedImmune will oversee all sales and mar- keting activities for FluMist, whose price was cut in half to $23.50 per dose; terms were not disclosed (6/15)
Pharmion Corp. (PHRM)
Ash Stevens Inc.
Ash Stevens got FDA approval to manufacture 5-azacitidine for Pharmion's Vidaza
Vidaza was approved May 20 for the treat- ment of myelodysplastic syndromes (5/21)
Pierce Biotechnology Inc.*
Tecan Group Ltd. (Switzerland)
Agreement to develop and co- market high-throughput screening solutions with fluorescence lifetime technology
They will combine technologies in the effort, and share product information and support; terms were not disclosed (5/17)
New England Biolabs
NEB licensed rights to RheoGene's RheoSwitch inducible gene regulation technology
NEB can develop and distribute research kits and related products based on the technology, and got nonexclusive rights to develop combination research products that incorporate the technology (6/8)
# The information in the chart does not cover agricultural agreements or those between biotech companies.
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; TSE = Toronto Stock Exchange.